Trastuzumab
- PDF / 169,237 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 12 Downloads / 137 Views
1 S
Hepatotoxicity: 2 case reports In an observational study of 64 patients, two patients [ages and sexes not stated] were described, who developed hepatotoxicity (elevated liver enzymes) during treatment with trastuzumab. The patients, who had HER2-positive breast cancer, started receiving trastuzumab [Herceptin; trastuzumab biosimilar; 1 patient] and trastuzumab [Ogivri; 1 patient; dosages and routes not stated]. Subsequently, the patients experienced elevations in liver enzymes (hepatotoxicity), of which, the patient receiving Herceptin developed hepatotoxicity after the first cycle of immunotherapy [not all duration of treatments to reaction onsets stated]. The patients eventually exhibited normalisation of liver enzyme levels. Cerina D, et al. Hepatotoxicity profiles of biosimilars vs. generic antiher2 therapy in everyday clinical practice- observational study at the department of oncology and radiotherapy, university hospital of split. Libri Oncologici 48 (Suppl. 1): 140-141 abstr. P40, 2020. Available from: URL: https://hrcak.srce.hr/ 803520409 index.php?show=clanak&id_clanak_jezik=353153 [abstract]
0114-9954/20/1834-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 12 Dec 2020 No. 1834
Data Loading...
